Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Cirrhosis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 231 articles:
HTML format
Text format



Single Articles


    February 2019
  1. NGUYEN MH
    Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30560.
    PubMed     Text format     Abstract available


  2. LAI SW, Lin CL
    Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30566.
    PubMed     Text format     Abstract available


  3. DEY P
    Carbon Tetrachloride (CCl4 )-Induced Classical Liver Cirrhosis Model: Revisiting The Mode Of Action.
    Hepatology. 2019 Feb 8. doi: 10.1002/hep.30555.
    PubMed     Text format     Abstract available


  4. ALBILLOS A, Munoz L, Alvarez-Mon M
    Reply to: Carbon Tetrachloride (CCl4)-Induced Classical Liver Cirrhosis Model: Revisiting The Mode Of Action.
    Hepatology. 2019 Feb 8. doi: 10.1002/hep.30554.
    PubMed     Text format     Abstract available


    January 2019
  5. SHALIMAR, Sheikh MF, Mookerjee RP, Agarwal B, et al
    Prognostic Role of Ammonia in Cirrhotic Patients.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30534.
    PubMed     Text format     Abstract available


  6. TAPPER EB
    Predicting Overt Hepatic Encephalopathy for the Population with Cirrhosis.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30533.
    PubMed     Text format     Abstract available


  7. ZEUZEM S, Bourgeois S, Greenbloom S, Buti M, et al
    JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1.
    Hepatology. 2019 Jan 28. doi: 10.1002/hep.30527.
    PubMed     Text format     Abstract available


  8. WONG GL, Liang LY, Kwok R, Hui AJ, et al
    Low risk of variceal bleeding in cirrhotic patients after variceal screening stratified by liver/spleen stiffness.
    Hepatology. 2019 Jan 25. doi: 10.1002/hep.30522.
    PubMed     Text format     Abstract available


  9. MAHMUD N, Kaplan DE, Taddei TH, Goldberg DS, et al
    Incidence and Mortality of Acute on Chronic Liver Failure using Two Definitions in Patients with Compensated Cirrhosis.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30494.
    PubMed     Text format     Abstract available


    December 2018
  10. KANWAL F, Tapper EB, Ho C, Asrani SK, et al
    Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Dec 26. doi: 10.1002/hep.30489.
    PubMed     Text format     Abstract available


  11. COTTER TG, Charlton M
    The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality from Cirrhosis.
    Hepatology. 2018 Dec 20. doi: 10.1002/hep.30408.
    PubMed     Text format     Abstract available


  12. SALMON-CERON D, Nahon P, Layese R, Bourcier V, et al
    HIV/HCV co-infected cirrhotic patients are no longer at higher risk for HCC or end-stage liver disease as compared to HCV mono-infected patients.
    Hepatology. 2018 Dec 19. doi: 10.1002/hep.30400.
    PubMed     Text format     Abstract available


  13. RAND EB
    Cirrhotic Cardiomyopathy in children with BA: A new objective parameter to predict morbidity and mortality on the waitlist - and beyond!
    Hepatology. 2018 Dec 12. doi: 10.1002/hep.30419.
    PubMed     Text format     Abstract available


  14. CLARIA J, Moreau R, Fenaille F, Amoros A, et al
    Orchestration of Tryptophan-Kynurenine pathway, acute decompensation and acute-on-chronic liver failure in cirrhosis.
    Hepatology. 2018 Dec 6. doi: 10.1002/hep.30363.
    PubMed     Text format     Abstract available


  15. SIMONETTO DA, Piccolo Serafim L, Gallo de Moraes A, Gajic O, et al
    Management of Sepsis in Patients with Cirrhosis: current evidence and practical approach.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30412.
    PubMed     Text format     Abstract available


  16. GIOIA S, Nardelli S, Riggio O
    Liver stiffness in non-cirrhotic portal hypertension - The Devil is in the diagnosis.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30367.
    PubMed     Text format     Abstract available


    November 2018
  17. NEONG SF, Billington EO, Congly SE
    Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: Review of pathogenesis and management.
    Hepatology. 2018 Nov 23. doi: 10.1002/hep.30359.
    PubMed     Text format     Abstract available


  18. MUNOZ L, Borrero MJ, Ubeda M, Conde E, et al
    Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis.
    Hepatology. 2018 Nov 10. doi: 10.1002/hep.30349.
    PubMed     Text format     Abstract available


  19. SHAHEEN AA, Swain MG
    Using proper methods to identify cirrhosis patients in administrative databases is crucial to correctly predict outcomes.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30343.
    PubMed     Text format     Abstract available


  20. TAPPER EB, Baki J, Parikh ND, Lok AS, et al
    Frailty, Psychoactive Medications, and Cognitive Dysfunction are Associated with Poor Patient-Reported Outcomes in Cirrhosis.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30336.
    PubMed     Text format     Abstract available


    October 2018
  21. CASTRO NARRO GE, Gamboa Dominguez A, Consuelo Sanchez A, Salazar Martinez A, et al
    Combined Hepatocellular-Cholangiocarcinoma in a Patient with Cirrhosis due to Cholesteryl Ester Storage Disease.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30331.
    PubMed     Text format     Abstract available


  22. KIM HL, An J, Park JA, Park SH, et al
    Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High Risk Patients with Cirrhosis.
    Hepatology. 2018 Oct 26. doi: 10.1002/hep.30330.
    PubMed     Text format     Abstract available


  23. VENTURA-COTS M, Watts AE, Cruz-Lemini M, Shah ND, et al
    Colder weather and fewer sunlight hours increase alcohol consumption and alcoholic cirrhosis worldwide.
    Hepatology. 2018 Oct 16. doi: 10.1002/hep.30315.
    PubMed     Text format     Abstract available


  24. ABRALDES JG, Trebicka J, Chalasani N, D'Amico G, et al
    Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension.
    Hepatology. 2018 Oct 15. doi: 10.1002/hep.30314.
    PubMed     Text format     Abstract available


  25. NARDELLI S, Gioia S, Ridola L, Farcomeni A, et al
    Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30304.
    PubMed     Text format     Abstract available


    September 2018
  26. VOLK M, Mellinger J, Bansal MB, Gellad ZF, et al
    A Roadmap for Value-Based Payment Models among Patients with Cirrhosis.
    Hepatology. 2018 Sep 18. doi: 10.1002/hep.30277.
    PubMed     Text format     Abstract available


  27. MUMTAZ K, Issak A, Porter K, Kelly S, et al
    Validation of Risk Score in Predicting Early Readmissions in Decompensated Cirrhotic patients: A Model Based on the Administrative Database.
    Hepatology. 2018 Sep 15. doi: 10.1002/hep.30274.
    PubMed     Text format     Abstract available


  28. RAEVENS S, Colle I
    Why pulse oximetry is inaccurate in liver cirrhosis - ancient knowledge.
    Hepatology. 2018 Sep 8. doi: 10.1002/hep.30260.
    PubMed     Text format     Abstract available


    August 2018
  29. ALLEGRETTI AS, Parada XV, Ortiz GA, Long J, et al
    Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30230.
    PubMed     Text format     Abstract available


  30. YKI-JARVINEN H
    Diabetes, liver cancer and cirrhosis: What next?
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30136.
    PubMed     Text format     Abstract available


  31. ALCARAZ-QUILES J, Casulleras M, Oettl K, Titos E, et al
    Oxidized albumin triggers a cytokine storm in leukocytes through p38 MAP kinase: role in systemic inflammation in decompensated cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30135.
    PubMed     Text format     Abstract available


  32. GANE EJ, Stedman CA, Schwabe C, Vijgen L, et al
    Short Duration AL-335, Odalasvir, With/Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30126.
    PubMed     Text format     Abstract available


  33. DROLZ A, Horvatits T, Rutter K, Landahl F, et al
    Lactate improves prediction of short-term mortality in critically ill cirrhosis patients: a multinational study.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30151.
    PubMed     Text format     Abstract available


  34. SINGAL AG, Tiro JA, Murphy CC, Marrero JA, et al
    Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients with Cirrhosis: A Randomized Clinical Trial.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30129.
    PubMed     Text format     Abstract available


  35. DE MATTOS AZ, de Mattos AA
    Evaluating Prognosis of Patients With Acute-On-Chronic Liver Failure: Is the Simplest Score Good Enough?
    Hepatology. 2018;68:790.
    PubMed     Text format    


  36. HUANG R, Gao ZH, Tang A, Sebastiani G, et al
    Transient elastography is an unreliable marker of liver fibrosis in patients with portal vein thrombosis.
    Hepatology. 2018;68:783-785.
    PubMed     Text format    


  37. DUAN JL, Ruan B, Yan XC, Liang L, et al
    Endothelial Notch activation reshapes the angiocrine of sinusoidal endothelia to aggravate liver fibrosis and blunt regeneration in mice.
    Hepatology. 2018;68:677-690.
    PubMed     Text format     Abstract available


    July 2018
  38. GARCIA-TSAO G, Fuchs M, Shiffman M, Borg BB, et al
    Emricasan (IDN-6556) Lowers Portal Pressure in Patients with Compensated Cirrhosis and Severe Portal Hypertension.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30199.
    PubMed     Text format     Abstract available


  39. CORTES E, Lachowski D, Rice A, Chronopoulos A, et al
    RAR-beta is downregulated in HCC & cirrhosis and its expression inhibits myosin-driven activation and durotaxis in hepatic stellate cells.
    Hepatology. 2018 Jul 28. doi: 10.1002/hep.30193.
    PubMed     Text format     Abstract available


  40. VUPPALANCHI R, Mathur K, Pyko M, Samala N, et al
    Liver Stiffness Measurements in Patients with Non-cirrhotic Portal Hypertension - The Devil is In the Details.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30167.
    PubMed     Text format     Abstract available


  41. ROMAN E, Gely C, Flavia M, Poca M, et al
    Patients with compensated cirrhosis are also at risk of falling.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30180.
    PubMed     Text format     Abstract available


  42. NAVIN P, Hilscher M, Welle C, Mounajjed T, et al
    The Utility of MR Elastography to Differentiate Nodular Regenerative Hyperplasia from Cirrhosis.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30175.
    PubMed     Text format     Abstract available


  43. CINGOLANI F, Czaja MJ
    Oxidized Albumin - a Trojan Horse for p38 MAPK-Mediated Inflammation in Decompensated Cirrhosis.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30164.
    PubMed     Text format     Abstract available


  44. KIM D, Li AA, Perumpail BJ, Gadiparthi C, et al
    Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30161.
    PubMed     Text format     Abstract available


  45. VERMA N, Singh A, Singh V
    Reply.
    Hepatology. 2018;68:388.
    PubMed     Text format    


  46. HERNAEZ R, Kanwal F, El-Serag HB
    Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis.
    Hepatology. 2018;68:7-9.
    PubMed     Text format    


    June 2018
  47. PELLICANO R, Durazzo M
    Upper GI bleeding in cirrhotic patients: Which method to search for Helicobacter pylori infection?
    Hepatology. 2018 Jun 11. doi: 10.1002/hep.30108.
    PubMed     Text format    


  48. LAI S, Iwakiri Y
    Is miR-21 a potent target for liver fibrosis?
    Hepatology. 2018;67:2082-2084.
    PubMed     Text format    


    May 2018
  49. BLASI A, Calvo A, Prado V, Reverter E, et al
    Coagulation failure in patients with Acute-on-Chronic Liver Failure (ACLF) and decompensated cirrhosis: beyond INR.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30103.
    PubMed     Text format     Abstract available


  50. BAJAJ JS, Savidge T, Kassam ZA, Hylemon PB, et al
    Fecal Microbial Transplant for Antibiotic-Associated Disruption in Cirrhosis.
    Hepatology. 2018 May 18. doi: 10.1002/hep.30092.
    PubMed     Text format    


  51. MULLISH BH, McDonald JAK, Thursz MR, Marchesi JR, et al
    Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis is Restored by Fecal Transplant.
    Hepatology. 2018 May 18. doi: 10.1002/hep.30090.
    PubMed     Text format    


  52. PANG Y, Kartsonaki C, Turnbull I, Guo Y, et al
    Diabetes, plasma glucose and incidence of fatty liver, cirrhosis and liver cancer: A prospective study of 0.5 million people.
    Hepatology. 2018 May 7. doi: 10.1002/hep.30083.
    PubMed     Text format     Abstract available


  53. QI X, Mendez-Sanchez N, Mancuso A, Romeiro FG, et al
    Who should receive endoscopic variceal ligation after recovering from acute variceal bleeding?
    Hepatology. 2018;67:2057-2058.
    PubMed     Text format    


    April 2018
  54. CULLARO G, Park M, Lai JC
    "Normal" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients with Cirrhosis.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30058.
    PubMed     Text format     Abstract available


  55. YANG JD, Gores GJ
    Does Cirrhosis Associated with Well Controlled Viral Hepatitis Confer a Risk for Extrahepatic Cancer?
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30063.
    PubMed     Text format    


  56. IZZY M, Oh J, Watt KD
    Cirrhotic cardiomyopathy after transplantation: Neither the transient nor innocent bystander.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30040.
    PubMed     Text format     Abstract available


  57. BAJAJ JS, Kakiyama G, Savidge T, Takei H, et al
    Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis is Restored by Fecal Transplant.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30037.
    PubMed     Text format     Abstract available


  58. ALLAIRE M, Nahon P, Layese R, Bourcier V, et al
    Extra hepatic cancers are the leading cause of death in cirrhotic patients achieving HBV control or HCV eradication.
    Hepatology. 2018 Apr 16. doi: 10.1002/hep.30034.
    PubMed     Text format     Abstract available


  59. WENDUM D, Layese R, Ganne-Carrie N, Bourcier V, et al
    Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29927.
    PubMed     Text format     Abstract available


  60. XIE L, Yin J, Xia R, Zhuang G, et al
    Cost-effectiveness of antiviral treatment after resection in HBV-related hepatocellular carcinoma patients with compensated cirrhosis.
    Hepatology. 2018 Apr 7. doi: 10.1002/hep.29922.
    PubMed     Text format     Abstract available


  61. PERLEMUTER G
    Circulating bugs in blood in alcoholic liver disease!
    Hepatology. 2018;67:1207-1209.
    PubMed     Text format    


    March 2018
  62. PAYANCE A, Silva-Junior G, Bissonnette J, Tanguy M, et al
    Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29903.
    PubMed     Text format     Abstract available


  63. MELLINGER JL, Shedden K, Winder GS, Tapper E, et al
    The High Burden of Alcoholic Cirrhosis in Privately Insured Persons in the United States.
    Hepatology. 2018 Mar 26. doi: 10.1002/hep.29887.
    PubMed     Text format     Abstract available


  64. MOYLAN CA, Abdelmalek MF
    Nonalcoholic Fatty Liver Disease with Cirrhosis Increases Familial Risk for Advanced Fibrosis.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29879.
    PubMed     Text format    


  65. PHILIPS CA, Augustine P, Mathew S, Valiathan GC, et al
    Letter to the editor: Growth factor therapy for decompensated cirrhosis - Much ado about nothing?
    Hepatology. 2018 Mar 3. doi: 10.1002/hep.29866.
    PubMed     Text format    


  66. ABERG F
    Liver fibrosis scores in the general population: Better risk indices are needed!
    Hepatology. 2018;67:1186.
    PubMed     Text format    


    February 2018
  67. WU JF, Lee CS, Lin WH, Jeng YM, et al
    Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy.
    Hepatology. 2018 Feb 27. doi: 10.1002/hep.29856.
    PubMed     Text format     Abstract available


  68. HUANG AC, Mehta N, Dodge JL, Yao FY, et al
    Direct-acting Antivirals Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence after Local-Regional Therapy or Liver Transplant Waitlist Dropout.
    Hepatology. 2018 Feb 24. doi: 10.1002/hep.29855.
    PubMed     Text format     Abstract available


  69. FOSTER GR, Agarwal K, Cramp ME, Moreea S, et al
    Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial.
    Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852.
    PubMed     Text format     Abstract available


  70. CAREY W
    Statin Use In Cirrhosis from Fatty Liver Disease.
    Hepatology. 2018 Feb 14. doi: 10.1002/hep.29842.
    PubMed     Text format    


  71. MAZZAFERRO V, Droz Dit Busset M, Bhoori S
    Alpha-Fetoprotein (AFP) in liver transplantation for HCC: The lower, the better.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29835.
    PubMed     Text format    


    January 2018
  72. RIDOLA L, Riggio O
    Prediction of Hepatic Encephalopathy: Why disregard well known risk factors?
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29808.
    PubMed     Text format    


  73. BERENGUER J, Gil-Martin A, Jarrin I, Moreno A, et al
    All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29814.
    PubMed     Text format     Abstract available


  74. KOSTALLARI E, Hirsova P, Prasnicka A, Verma VK, et al
    Hepatic stellate cell-derived PDGFRalpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2.
    Hepatology. 2018 Jan 23. doi: 10.1002/hep.29803.
    PubMed     Text format     Abstract available


  75. BERZIGOTTI A, Bosch J
    Reply to "Balancing exercise-induced weight loss with protein caloric requirement remains a challenge in overweight patients with cirrhosis".
    Hepatology. 2018 Jan 22. doi: 10.1002/hep.29799.
    PubMed     Text format    


  76. DHALIWAL A, Towey J, Haydon G, Elsharkawy AM, et al
    Balancing exercise-induced weight loss with protein caloric requirement remains a challenge in overweight patients with cirrhosis.
    Hepatology. 2018 Jan 22. doi: 10.1002/hep.29801.
    PubMed     Text format    


  77. BAJAJ JS, Idilman R, Mabudian L, Hood M, et al
    Diet Affects Gut Microbiota and Modulates Hospitalization Risk Differentially In an International Cirrhosis Cohort.
    Hepatology. 2018 Jan 19. doi: 10.1002/hep.29791.
    PubMed     Text format     Abstract available


  78. GULAMHUSEIN AF, Lazaridis KN
    Primary Biliary Cholangitis, DNA and Beyond: The Relative Contribution of Genes.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29783.
    PubMed     Text format    


  79. BOTTCHER K, Rombouts K, Saffioti F, Roccarina D, et al
    MAIT cells are chronically activated in patients with autoimmune liver disease and promote pro-fibrogenic hepatic stellate cell activation.
    Hepatology. 2018 Jan 12. doi: 10.1002/hep.29782.
    PubMed     Text format     Abstract available


  80. PATIDAR KR, Kang L, Bajaj JS, Carl D, et al
    Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis.
    Hepatology. 2018 Jan 8. doi: 10.1002/hep.29772.
    PubMed     Text format     Abstract available


  81. O'LEARY JG, Reddy KR, Garcia-Tsao G, Biggins SW, et al
    NACSELD Acute-on-Chronic Liver Failure (NACSELD-ACLF) Score Predicts 30-Day Survival in Hospitalized Patients with Cirrhosis.
    Hepatology. 2018 Jan 8. doi: 10.1002/hep.29773.
    PubMed     Text format     Abstract available


  82. HERRMANN E, de Ledinghen V, Cassinotto C, Chu WC, et al
    Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis.
    Hepatology. 2018;67:260-272.
    PubMed     Text format     Abstract available


  83. WREE A, Inzaugarat ME, Feldstein AE
    Transmembrane BAX Inhibitor motif-containing 1, a novel anti-inflammatory approach for nonalcoholic steatohepatitis treatment.
    Hepatology. 2018;67:438-441.
    PubMed     Text format    


  84. SINGH S, Loomba R
    Role of two-dimensional shear wave elastography in the assessment of chronic liver diseases.
    Hepatology. 2018;67:13-15.
    PubMed     Text format    


    December 2017
  85. VERMA N, Kaur A, Sharma R, Bhalla A, et al
    Outcomes after Multiple courses of Granulocyte-Colony Stimulating Factor and Growth Hormone in Decompensated Cirrhosis: Randomized Trial.
    Hepatology. 2017 Dec 26. doi: 10.1002/hep.29763.
    PubMed     Text format     Abstract available


  86. TAPPER EB, Kanwal F, Asrani SK, Ho C, et al
    Patient Reported Outcomes in Cirrhosis: A Scoping Review of the Literature.
    Hepatology. 2017 Dec 22. doi: 10.1002/hep.29756.
    PubMed     Text format     Abstract available


  87. TAPPER EB, Lok AS, Su GL
    Re: Risk stratification of suffering hepatic encephalopathy in liver cirrhosis patients: novel strategy with novel concerns.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29746.
    PubMed     Text format    


  88. ZHENG B, Zhu YJ, Jeong S, Wang HY, et al
    Risk stratification ofhepatic encephalopathy in liver cirrhosis patients: Novel strategy with novel concerns.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29747.
    PubMed     Text format    


  89. SU TH, Tseng TC, Kao JH
    HCC risk in patients with HBV-related cirrhosis receiving NA therapy: is HCC prevented or delayed?
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29740.
    PubMed     Text format    


  90. SPELIOTES EK
    Thwart your destiny; effect of NAFLD genes on steatosis, liver injury and cirrhosis varies by body mass index.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29739.
    PubMed     Text format    


  91. BRISEBOIS A, Ismond KP, Carbonneau M, Tandon P, et al
    Advance Care Planning (ACP) for specialists managing cirrhosis: a focus on patient-centered care.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29731.
    PubMed     Text format     Abstract available


  92. ZOU X, Ramachandran P, Kendall TJ, Pellicoro A, et al
    11betaHSD1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29734.
    PubMed     Text format     Abstract available


  93. GARCIA-TSAO G
    Regression of HCV cirrhosis: Time will tell.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29720.
    PubMed     Text format    


  94. LEVY C
    Evolving role of Obeticholic acid in primary biliary cholangitis.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29726.
    PubMed     Text format    


  95. YOUNOSSI ZM, Loomba R, Anstee QM, Rinella ME, et al
    Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29721.
    PubMed     Text format     Abstract available


  96. MURILLO PEREZ F, Goet JC, Lammers WJ, Gulamhusein A, et al
    Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29717.
    PubMed     Text format     Abstract available


    November 2017
  97. SINGH AK, Rooge SB, Varshney A, Vasudevan M, et al
    Global micro RNA expression profiling in the liver biopsies of Hepatitis B Virus infected patients suggests specific miRNA signatures for viral persistence and hepatocellular injury.
    Hepatology. 2017 Nov 30. doi: 10.1002/hep.29690.
    PubMed     Text format     Abstract available


  98. CHANG FM, Wang YP, Lu CL
    Reply: Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29686.
    PubMed     Text format    


  99. LIN CY
    Statins and risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: Methodological issues.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29687.
    PubMed     Text format    


  100. LO GH, Reiberger T
    Peptic ulcer bleeding in cirrhotic patients: Is as bad as variceal bleeding?
    Hepatology. 2017 Nov 23. doi: 10.1002/hep.29680.
    PubMed     Text format     Abstract available


  101. ORNOLFSSON KT, Olafsson S, Bergmann OM, Gershwin ME, et al
    Using the Icelandic Genealogical Database to define the familial risk of primary biliary cholangitis.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29675.
    PubMed     Text format     Abstract available


  102. PARK H, O'Brien TR, Rehermann B
    The role of genetics in hepatic fibrosis amongst HCV patients.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29659.
    PubMed     Text format    


  103. AFONSO MB, Rodrigues CMP
    microRevolution in understanding primary biliary cholangitis pathophysiology.
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29653.
    PubMed     Text format    


  104. KAFFE E, Fiorotto R, Pellegrino F, Mariotti V, et al
    beta-catenin and IL-1beta dependent CXCL10 production drives progression of disease in a mouse model of Congenital Hepatic Fibrosis.
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29652.
    PubMed     Text format     Abstract available


  105. FAGGIOLI F, Palagano E, Di Tommaso L, Donadon M, et al
    B lymphocytes limit senescence-driven fibrosis resolution and favor hepatocarcinogenesis in mouse liver injury.
    Hepatology. 2017 Nov 3. doi: 10.1002/hep.29636.
    PubMed     Text format     Abstract available


  106. TAPPER EB, Parikh N, Sengupta N, Mellinger J, et al
    A Risk Score to Predict the Development of Hepatic Encephalopathy in a Population-Based Cohort of Patients with Cirrhosis.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29628.
    PubMed     Text format     Abstract available


  107. XIAO G, Zhu S, Xiao X, Yan L, et al
    Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.
    Hepatology. 2017;66:1486-1501.
    PubMed     Text format     Abstract available


  108. XANTHAKOS SA, Trout AT, Dillman JR
    Magnetic resonance elastography assessment of fibrosis in children with NAFLD: Promising but not perfect.
    Hepatology. 2017;66:1373-1376.
    PubMed     Text format    


  109. CARBONE M, Bonato G, Invernizzi P
    Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29625.
    PubMed     Text format    


  110. CAVIGLIA JM, Yan J, Jang MK, Gwak GY, et al
    MicroRNA-21 and Dicer are Dispensable for Hepatic Stellate Cell Activation and the Development of Liver Fibrosis.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29627.
    PubMed     Text format     Abstract available


    October 2017
  111. LIASKOU E, Hirschfield GM
    Genetic association studies and the risk factors for developing the 'immuno-bile-logic' disease PBC.
    Hepatology. 2017 Oct 24. doi: 10.1002/hep.29603.
    PubMed     Text format    


  112. PRAKTIKNJO M, Book M, Luetkens J, Pohlmann A, et al
    Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29602.
    PubMed     Text format     Abstract available


  113. PHILIPS CA, Kumar L, Augustine P
    Partial Splenic Artery Embolization for Severe Hepatic Myelopathy in Cirrhosis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29597.
    PubMed     Text format     Abstract available


  114. YANG JD, Mannalithara A, Piscitello AJ, Kisiel JB, et al
    Impact of Surveillance for Hepatocellular Carcinoma on Survival in Patients with Compensated Cirrhosis.
    Hepatology. 2017 Oct 12. doi: 10.1002/hep.29594.
    PubMed     Text format     Abstract available


  115. MONTANO-LOZA AJ, Mazurak VC, Ebadi M, Meza-Junco J, et al
    Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29578.
    PubMed     Text format     Abstract available


  116. MACDONALD S, Andreola F, Bachtiger P, Amoros A, et al
    Cell death markers in cirrhotic patients with acute decompensation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29581.
    PubMed     Text format     Abstract available


  117. KOWDLEY KV, Luketic V, Chapman R, Hirschfield GM, et al
    A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29569.
    PubMed     Text format     Abstract available


  118. RAEVENS S, Geerts A, Paridaens A, Lefere S, et al
    Placental growth factor inhibition targets pulmonary angiogenesis and represents a novel therapy for hepatopulmonary syndrome in mice.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29579.
    PubMed     Text format     Abstract available


  119. ALBILLOS A, Zamora J, Martinez J, Arroyo D, et al
    Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.
    Hepatology. 2017;66:1219-1231.
    PubMed     Text format     Abstract available


  120. SO-ARMAH KA, Lim JK, Lo Re V, Tate JP, et al
    FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.
    Hepatology. 2017;66:1286-1295.
    PubMed     Text format     Abstract available


  121. BANGEN JM, Hammerich L, Sonntag R, Baues M, et al
    Targeting CCl4 -induced liver fibrosis by RNA interference-mediated inhibition of cyclin E1 in mice.
    Hepatology. 2017;66:1242-1257.
    PubMed     Text format     Abstract available


  122. LIU Z, Que S, Mardinoglu A
    Rediscussion on linearity between fibrosis stages and mortality risk in nonalcoholic fatty liver disease patients.
    Hepatology. 2017;66:1357-1358.
    PubMed     Text format    


  123. SAFIRI S, Khazaei S, Mansori K, Ayubi E, et al
    Comments on "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis".
    Hepatology. 2017;66:1358-1359.
    PubMed     Text format    


    September 2017
  124. MAURO E, Crespo G, Montironi C, Londono MC, et al
    Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29557.
    PubMed     Text format     Abstract available


  125. PHILIPS CA, Augustine P
    Plasma biomarkers to diagnose alcoholic hepatitis - are we there yet?
    Hepatology. 2017 Sep 23. doi: 10.1002/hep.29547.
    PubMed     Text format    


  126. KRENKEL O, Puengel T, Govaere O, Abdallah AT, et al
    Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis.
    Hepatology. 2017 Sep 21. doi: 10.1002/hep.29544.
    PubMed     Text format     Abstract available


  127. WYLES D, Poordad F, Wang S, Alric L, et al
    Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.
    PubMed     Text format     Abstract available


  128. ERICE O, Munoz-Garrido P, Vaquero J, Perugorria MJ, et al
    MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.
    Hepatology. 2017 Sep 18. doi: 10.1002/hep.29533.
    PubMed     Text format     Abstract available


  129. CESARI M, Frigo AC, Tonon M, Angeli P, et al
    Cardiovascular predictors of death in patients with cirrhosis.
    Hepatology. 2017 Sep 13. doi: 10.1002/hep.29520.
    PubMed     Text format     Abstract available


  130. BORENTAIN P, Colson P, Bolon E, Gauchez P, et al
    Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29508.
    PubMed     Text format    


  131. DELLAVANCE A, Ferraz MLG, Cancado ELR, Andrade LEC, et al
    Expansion and intensification of humoral autoimmune response in the transition from preclinical to full-blown primary biliary cholangitis.
    Hepatology. 2017;66:997.
    PubMed     Text format    


    August 2017
  132. FRIEDMAN SL, Ratziu V, Harrison SA, Abdelmalek MF, et al
    A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.
    Hepatology. 2017 Aug 17. doi: 10.1002/hep.29477.
    PubMed     Text format     Abstract available


  133. DE HAAS RJ, Lim C, Bhangui P, Salloum C, et al
    Curative Salvage Liver Transplantation in Cirrhotic patients with Hepatocellular Carcinoma: An intention-to-treat analysis.
    Hepatology. 2017 Aug 14. doi: 10.1002/hep.29468.
    PubMed     Text format     Abstract available


  134. MATSUDA M, Tsurusaki S, Miyata N, Saijou E, et al
    Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice.
    Hepatology. 2017 Aug 5. doi: 10.1002/hep.29421.
    PubMed     Text format     Abstract available


  135. LAI JC, Covinsky KE, Dodge JL, Boscardin WJ, et al
    Development of a novel frailty index to predict mortality in patients with end-stage liver disease.
    Hepatology. 2017;66:564-574.
    PubMed     Text format     Abstract available


  136. HE Y, Gao B
    A small specific-sized hyaluronic acid ameliorates alcoholic liver disease by targeting a small RNA: New hope for therapy?
    Hepatology. 2017;66:321-323.
    PubMed     Text format    


    July 2017
  137. SAUERBRUCH T
    Continuation of non-selective beta-blockers for patients with liver cirrhosis and hemodynamic non-response?
    Hepatology. 2017 Jul 22. doi: 10.1002/hep.29394.
    PubMed     Text format    


  138. PEDERSEN JS, Kimer N, Henriksen JH, Bendtsen F, et al
    The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort.
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29386.
    PubMed     Text format    


  139. KALAFATELI M, Tsochatzis EA
    Reply to "The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort."
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29391.
    PubMed     Text format    


  140. ARDEVOL A, Ibanez-Sanz G, Profitos J, Aracil C, et al
    Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29370.
    PubMed     Text format     Abstract available


  141. SIMONETTO DA, Kamath PS, Shah VH
    Alcoholic Hepatitis: Continued drinking and the mourning after.
    Hepatology. 2017 Jul 3. doi: 10.1002/hep.29349.
    PubMed     Text format    


  142. UNALP-ARIDA A, Ruhl CE
    Liver fibrosis scores predict liver disease mortality in the United States population.
    Hepatology. 2017;66:84-95.
    PubMed     Text format     Abstract available


    June 2017
  143. CHIDA T, Ito M, Nakashima K, Kanegae Y, et al
    Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.
    PubMed     Text format     Abstract available


  144. GIANNINI EG, Savarino V
    Noninvasive assessment of varices needing treatment in patients with advanced chronic liver disease: No one should be left behind.
    Hepatology. 2017;65:2131.
    PubMed     Text format    


  145. KARLAS T, Beer S, Babel J, Busse H, et al
    Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease patients?
    Hepatology. 2017;65:2126-2128.
    PubMed     Text format    


    May 2017
  146. MARKWARDT D, Holdt L, Steib C, Benesic A, et al
    Plasma Cystatin C is a predictor of renal dysfunction, ACLF and mortality in patients with acutely decompensated liver cirrhosis.
    Hepatology. 2017 May 25. doi: 10.1002/hep.29290.
    PubMed     Text format     Abstract available


  147. CHIANG JYL
    Linking long non-coding RNA to control bile acid signaling and cholestatic liver fibrosis.
    Hepatology. 2017 May 24. doi: 10.1002/hep.29289.
    PubMed     Text format    


  148. WANG Z, Han J, Zhang H, Wu MC, et al
    Emphasis on Harms of Hepatocellular Carcinoma Surveillance: Just Pretending Innocent After Taking Advantages?
    Hepatology. 2017 May 24. doi: 10.1002/hep.29288.
    PubMed     Text format    


  149. TSOCHATZIS EA, Bosch J
    Statins in cirrhosis - ready for prime time.
    Hepatology. 2017 May 22. doi: 10.1002/hep.29277.
    PubMed     Text format    


  150. O'HARA SP, LaRusso NF
    Cellular Senescence, Neuropeptides and Hepatic Fibrosis: Additional Insights into Increasing Complexity.
    Hepatology. 2017 May 2. doi: 10.1002/hep.29243.
    PubMed     Text format    


  151. LACKNER C, Bataller R, Burt A, Miquel R, et al
    Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?
    Hepatology. 2017;65:1758-1761.
    PubMed     Text format    


  152. LING Z, Liu X, Cheng Y, Shao L, et al
    Blood microbiota as a potential noninvasive diagnostic biomarker for liver fibrosis in severely obese patients: Choose carefully.
    Hepatology. 2017;65:1775-1776.
    PubMed     Text format    


  153. MARTINEZ J, Tellez L, Albillos A
    Acute variceal bleeding in patients on primary prophylaxis with nonselective beta-blockers: A poor prognosis factor?
    Hepatology. 2017;65:1774.
    PubMed     Text format    


  154. VUPPALANCHI R, Saxena R, Storniolo AMV, Chalasani N, et al
    Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib.
    Hepatology. 2017;65:1762-1764.
    PubMed     Text format    


    April 2017
  155. SONG Y, Liu C, Liu X, Trottier J, et al
    H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29209.
    PubMed     Text format     Abstract available


  156. HADJIHAMBI A, De Chiara F, Hosford PS, Habtetion A, et al
    Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease.
    Hepatology. 2017;65:1306-1318.
    PubMed     Text format     Abstract available


  157. BALIGAR P, Kochat V, Arindkar SK, Equbal Z, et al
    Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human alpha1-antitrypsin.
    Hepatology. 2017;65:1319-1335.
    PubMed     Text format     Abstract available


  158. HALL Z, Bond NJ, Ashmore T, Sanders F, et al
    Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
    Hepatology. 2017;65:1165-1180.
    PubMed     Text format     Abstract available


  159. PETTA S, Wong VW, Camma C, Hiriart JB, et al
    Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
    Hepatology. 2017;65:1145-1155.
    PubMed     Text format     Abstract available


  160. FORREST E
    Clinical Criteria are Critical to Diagnosing Alcoholic Hepatitis.
    Hepatology. 2017 Apr 1. doi: 10.1002/hep.29188.
    PubMed     Text format    


    March 2017
  161. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Text format     Abstract available


  162. DE MATTOS AZ, Miozzo SA, Tovo CV, de Mattos AA, et al
    Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29132.
    PubMed     Text format    


  163. MOLLER S, Hove JD
    Assessment of systolic function in the evaluation of patients with cirrhosis.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29163.
    PubMed     Text format    


  164. SURAWEERA D, Saab S
    Hepatitis C Treatment Threshold in Patients with Decompensated Liver Disease.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29175.
    PubMed     Text format    


  165. CAMPAGNA F, Montagnese S, Ridola L, Senzolo M, et al
    The animal naming test: An easy tool for the assessment of hepatic encephalopathy.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29146.
    PubMed     Text format     Abstract available


  166. LI X, Liu R, Yang J, Sun L, et al
    The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2-/- mice.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29145.
    PubMed     Text format     Abstract available


  167. WAN Y, Meng F, Wu N, Zhou T, et al
    Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29138.
    PubMed     Text format     Abstract available


  168. MAIERS JL, Kostallari E, Mushref M, deAssuncao TM, et al
    The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice.
    Hepatology. 2017;65:983-998.
    PubMed     Text format     Abstract available


  169. ZHU B, Wei L, Rotile N, Day H, et al
    Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model.
    Hepatology. 2017;65:1015-1025.
    PubMed     Text format     Abstract available


  170. KISSELEVA T
    The origin of fibrogenic myofibroblasts in fibrotic liver.
    Hepatology. 2017;65:1039-1043.
    PubMed     Text format     Abstract available


    February 2017
  171. DAM G, Vilstrup H, Watson H, Jepsen P, et al
    Reply to letter from de Mattos and colleagues: Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Feb 21. doi: 10.1002/hep.29131.
    PubMed     Text format    


  172. YOTTI R, Ripoll C, Benito Y, Catalina MV, et al
    Left ventricular systolic function is associated to sympathetic nervous activity and markers of inflammation in cirrhosis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29104.
    PubMed     Text format     Abstract available


  173. KUMAR A, Davuluri G, deSilva RN, Engelen MP, et al
    Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29107.
    PubMed     Text format    


  174. BRUDEN DJ, McMahon BJ, Townshend-Bulson L, Gounder P, et al
    Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29115.
    PubMed     Text format     Abstract available


  175. GOLDSWORTHY MA, Rowe IA
    Patient understanding of hepatocellular carcinoma surveillance.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29103.
    PubMed     Text format    


  176. KRAWCZYK M, Rau M, Grunhage F, Schattenberg JM, et al
    The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29100.
    PubMed     Text format    


  177. FERNANDEZ CARRILLO C, Lens S, Llop E, Pascasio JM, et al
    Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry.
    Hepatology. 2017 Feb 7. doi: 10.1002/hep.29097.
    PubMed     Text format     Abstract available


  178. ZUBIETE-FRANCO I, Fernandez-Tussy P, Barbier-Torres L, Simon J, et al
    Deregulated neddylation in liver fibrosis.
    Hepatology. 2017;65:694-709.
    PubMed     Text format     Abstract available


  179. TEDESCO D, Thapa M, Gumber S, Elrod EJ, et al
    CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.
    Hepatology. 2017;65:661-677.
    PubMed     Text format     Abstract available


  180. THIELE M, Madsen BS, Krag A
    Is liver stiffness equal to liver fibrosis?
    Hepatology. 2017;65:749.
    PubMed     Text format    


    January 2017
  181. VILASECA M, Garcia-Caldero H, Lafoz E, Garcia-Irigoyen O, et al
    The anticoagulant Rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
    Hepatology. 2017 Jan 31. doi: 10.1002/hep.29084.
    PubMed     Text format     Abstract available


  182. WANG Y, Vincent R, Yang J, Asgharpour A, et al
    Dual photon microscopy based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.
    Hepatology. 2017 Jan 30. doi: 10.1002/hep.29090.
    PubMed     Text format     Abstract available


  183. WANG Y, Aoki H, Yang J, Peng K, et al
    The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29076.
    PubMed     Text format     Abstract available


  184. HARGROVE L, Kennedy L, Demieville J, Jones H, et al
    BDL-induced biliary hyperplasia, hepatic injury and fibrosis are reduced in mast cell deficient Kitw-sh mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29079.
    PubMed     Text format     Abstract available


  185. THABET K, Chan HL, Petta S, Mangia A, et al
    The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.
    Hepatology. 2017 Jan 20. doi: 10.1002/hep.29064.
    PubMed     Text format     Abstract available


  186. SABATE A, Blasi A
    Thromboelastography and blood product usage in cirrhosis with severe coagulopathy.
    Hepatology. 2017 Jan 19. doi: 10.1002/hep.29061.
    PubMed     Text format    


  187. VILLANUEVA C, Graupera I, Aracil C, Alvarado E, et al
    A Randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29056.
    PubMed     Text format     Abstract available


  188. DRIVER R, Rowe IA
    What is the benefit of early follow-up after hospitalization for patients with cirrhosis?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29060.
    PubMed     Text format    


  189. MARONI L, Hohenester SD, van de Graaf SF, Tolenaars D, et al
    Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice.
    Hepatology. 2017 Jan 5. doi: 10.1002/hep.29029.
    PubMed     Text format     Abstract available


  190. ALCARAZ-QUILES J, Titos E, Casulleras M, Pavesi M, et al
    Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure.
    Hepatology. 2017;65:202-216.
    PubMed     Text format     Abstract available


  191. DECARIS ML, Li KW, Emson CL, Gatmaitan M, et al
    Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.
    Hepatology. 2017;65:78-88.
    PubMed     Text format     Abstract available


    December 2016
  192. TANDON P, Raman M, Mourtzakis M, Merli M, et al
    A Practical Approach to Nutritional Screening and Assessment in Cirrhosis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29003.
    PubMed     Text format     Abstract available


  193. BERZIGOTTI A, Albillos A, Villanueva C, Genesca J, et al
    Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The sportdiet study.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28992.
    PubMed     Text format     Abstract available


  194. KAFFE E, Katsifa A, Xylourgidis N, Ninou I, et al
    Hepatocyte Autotaxin expression promotes liver fibrosis and cancer.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28973.
    PubMed     Text format     Abstract available


  195. MARTINI S, Salizzoni M, David E, Tandoi F, et al
    Favorable short-term outcome of HCV-positive liver graft with bridging fibrosis: A plea for very early viral eradication.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28978.
    PubMed     Text format     Abstract available


  196. HERNAEZ R, El-Serag H, DeBakey ME
    Hepatocellular Carcinoma Surveillance: The Road Ahead.
    Hepatology. 2016 Dec 10. doi: 10.1002/hep.28983.
    PubMed     Text format    


    November 2016
  197. ASKGAARD G, Leon DA, Kjaer MS, Deleuran T, et al
    Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: A nationwide prospective cohort study.
    Hepatology. 2016 Nov 16. doi: 10.1002/hep.28943.
    PubMed     Text format     Abstract available


  198. NEWBERRY EP, Xie Y, Kennedy SM, Graham MJ, et al
    Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in Liver fatty acid binding protein null mice.
    Hepatology. 2016 Nov 14. doi: 10.1002/hep.28941.
    PubMed     Text format     Abstract available


  199. VAN ASTEN M, Verhaegh P, Koek G, Verbeek J, et al
    The increasing burden of NAFLD fibrosis in the general population: Time to bridge the gap between hepatologists and primary care.
    Hepatology. 2016 Nov 10. doi: 10.1002/hep.28940.
    PubMed     Text format    


  200. CALDWELL S, Lisman T
    The cirrhotic platelet: Shedding light on an enigma.
    Hepatology. 2016 Nov 7. doi: 10.1002/hep.28931.
    PubMed     Text format    


  201. MASSEY VL, Dolin CE, Poole LG, Hudson SV, et al
    The hepatic "matrisome" responds dynamically to injury: Characterization of transitional changes to the extracellular matrix in mice.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28918.
    PubMed     Text format     Abstract available


  202. DESBOROUGH MJ, Kahan BC, Stanworth SJ, Jairath V, et al
    Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding.
    Hepatology. 2016 Nov 3. doi: 10.1002/hep.28915.
    PubMed     Text format    


  203. DROLZ A, Fuhrmann V
    "Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding".
    Hepatology. 2016 Nov 3. doi: 10.1002/hep.28914.
    PubMed     Text format    


    October 2016
  204. GARCIA-TSAO G, Abraldes J, Berzigotti A, Bosch J, et al
    Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis and Management - 2016 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2016 Oct 27. doi: 10.1002/hep.28906.
    PubMed     Text format    


  205. KALAFATELI M, Wickham F, Burniston M, Cholongitas E, et al
    Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The rfh cirrhosis Gfr.
    Hepatology. 2016 Oct 25. doi: 10.1002/hep.28891.
    PubMed     Text format     Abstract available


  206. TANDON P, Reddy KR, O'Leary JG, Garcia-Tsao G, et al
    A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28900.
    PubMed     Text format     Abstract available


  207. ATIQ O, Tiro J, Yopp AC, Muffler A, et al
    An Assessment of Benefits and Harms of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28895.
    PubMed     Text format     Abstract available


  208. KIMER N, Pedersen JS, Busk TM, Gluud LL, et al
    Rifaximin has no effect on hemodynamics in decompensated cirrhosis - A randomized, double blind, placebo controlled trial.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28898.
    PubMed     Text format     Abstract available


  209. LABONTE AC, Sung SJ, Jennelle LT, Dandekar AP, et al
    Expression of scavenger receptor-AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28873.
    PubMed     Text format     Abstract available


  210. PARIKH ND, Marshall VD, Singal AG, Nathan H, et al
    Survival and Cost-Effectiveness of Sorafenib Therapy in Advanced Hepatocellular Carcinoma: An Analysis of the SEER-Medicare Database.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28881.
    PubMed     Text format     Abstract available


  211. WRANKE A, Calle Serrano B, Heidrich B, Kirschner J, et al
    Antiviral treatment and liver-related complications in hepatitis delta.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28876.
    PubMed     Text format     Abstract available


  212. MAROT A, Vandenbulcke H, Knebel JF, Doerig C, et al
    External validation of the nomogram for individualized prediction of HCC occurrence in patients with HCV-related compensated cirrhosis.
    Hepatology. 2016 Oct 13. doi: 10.1002/hep.28865.
    PubMed     Text format    


    September 2016
  213. ALI KHAN M, Cholankeril G, Howden CW
    Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast.
    Hepatology. 2016 Sep 30. doi: 10.1002/hep.28858.
    PubMed     Text format    


  214. PONZETTO A, Srinivasan RS
    Risk factors for hepatocellular carcinoma.
    Hepatology. 2016 Sep 28. doi: 10.1002/hep.28854.
    PubMed     Text format    


  215. LO GH
    The risk of bleeding after invasive procedures in cirrhotics with severe coagulopathy.
    Hepatology. 2016 Sep 26. doi: 10.1002/hep.28855.
    PubMed     Text format    


  216. CUSI K
    Nonalcoholic Steatohepatitis in Non-Obese Patients: Not So Different After All.
    Hepatology. 2016 Sep 20. doi: 10.1002/hep.28839.
    PubMed     Text format    


  217. RAPARELLI V, Basili S, Carnevale R, Napoleone L, et al
    Low-grade endotoxemia and platelet activation in cirrhosis.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28853.
    PubMed     Text format     Abstract available


  218. AMARAPURKAR D, Somani V, Shah A
    Do we need to correct coagulation abnormalities prophylactically in cirrhotics undergoing invasive procedures? - A Dilemma.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28830.
    PubMed     Text format    


  219. ABRALDES JG, Bureau C, Stefanescu H, Augustin S, et al
    Non-invasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28824.
    PubMed     Text format     Abstract available


  220. RENOU C, Lesgourgues B, Macaigne G, Pauwels A, et al
    Hepatitis E in decompensated alcoholic cirrhosis.
    Hepatology. 2016 Sep 12. doi: 10.1002/hep.28792.
    PubMed     Text format    


    August 2016
  221. SALLOUM S, Holmes JA, Jindal R, Bale SS, et al
    HIV/HCV in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28766.
    PubMed     Text format     Abstract available


    July 2016
  222. VERGANI D, Mieli-Vergani G
    Mouse model of primary biliary cholangitis with a striking female predominance: A new powerful research tool.
    Hepatology. 2016 Jul 7. doi: 10.1002/hep.28718.
    PubMed     Text format    


    June 2016
  223. ULVELING D, Le Clerc S, Cobat A, Labib T, et al
    A new 3p25 locus is associated with liver fibrosis progression in HIV/HCV co-infected patients.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28695.
    PubMed     Text format     Abstract available


  224. CUI J, Chen CH, Lo MT, Schork N, et al
    Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study.
    Hepatology. 2016 Jun 17. doi: 10.1002/hep.28674.
    PubMed     Text format     Abstract available


    May 2016
  225. MATSUURA K, De Giorgi V, Schechterly C, Wang RY, et al
    Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28660.
    PubMed     Text format     Abstract available


    April 2016
  226. WU N, Meng F, Invernizzi P, Bernuzzi F, et al
    The secretin/secretin receptor axis modulates liver fibrosis through changes in TGF-beta1 biliary secretion.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28622.
    PubMed     Text format     Abstract available


  227. VERLINDEN W, Francque S, Michielsen P, Vanwolleghem T, et al
    Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28610.
    PubMed     Text format    


  228. LIU J, Yang HI, Lee MH, Jen CL, et al
    Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.
    Hepatology. 2016 Apr 15. doi: 10.1002/hep.28552.
    PubMed     Text format     Abstract available


    March 2016
  229. ARAB JP, Shah VH
    Statins and portal hypertension: A tale of two models.
    Hepatology. 2016 Mar 25. doi: 10.1002/hep.28567.
    PubMed     Text format    


  230. ABRALDES JG, Burak KW
    STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma?
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28537.
    PubMed     Text format    


    January 2016
  231. DESAI SS, Tung JC, Zhou VX, Grenert JP, et al
    Physiological Ranges of Matrix Rigidity Modulate Primary Mouse Hepatocyte Function In Part Through Hepatocyte Nuclear Factor 4 Alpha.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28450.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: